![]() | |||||
|
The ERAB e-Newsletter - Issue 2
Welcome
ERAB would like to welcome all the new subscribers to the ERAB e-Newsletter.
In this issue you will find details of the grant applications received this year and an invitation to the International Medical Advisory Group Conference in Italy in October.
Grant Applications
The deadline for the 2010 applications was 5th April. We are delighted to announce that we have received a record number of applications covering a wide variety of subjects including Cardiovascular disease, Liver disease, Genetics, Neurological Disease, Drinking and driving, Adolescent drinking, Social influence and Treatment.
Applications were received from 12 European countries as follows, Belgium (2), Switzerland (1), Denmark (1), Spain (4), Finland (1), France (2), Croatia (1), Ireland (1), Italy (6), The Netherlands (5), Sweden (2) and UK (12).
The Advisory Board met in May to suggest reviewers who will be asked to review the applications during the course of the summer. They will meet again in October to decide, on the basis of the reviews, which applications should be funded. Applicants will be notified after the ERAB Board meetings.
The deadline for applications for 2011 is Monday 11th April.
International Medical Advisory Group Conference
This year ERAB is organising the 36th International Medical Advisory Group (IMAG) Conference in Frascati, Italy on Monday 18th and Tuesday 19th October 2010. This conference will be a showcase for the research projects which ERAB has funded in the last few years and will also provide overviews on the current knowledge for key areas of research such as binge drinking and risk factors for harmful consumption. It is also a key forum for the exchange of knowledge between scientists working in the field from all over the world. In particular many colleagues from the USA and Canada will be attending, as the ABMRF/The Foundation for Alcohol Research will participate in this conference. The draft programme follows.
ERAB would like to invite researchers working in the field of alcohol research to attend the scientific sessions of this conference. There is no charge to attend this conference but delegates are required to pay for their travel and accommodation. Low cost fights land at Ciampino airport, just 15 minutes from the hotel, and the single room rate is €59.00.
To register and book accommodation please click here. Accommodation in and around Rome will be a at premium during the week of the conference so if you are interested in attending please register as soon as possible. If you would like further information about the conference please contact Janet Witheridge, ERAB Secretary-General at j.witheridge@erab.org
Programme for the 36th IMAG
Monday 18th October 2010
08.30 Official Opening of 36th IMAG. KEYNOTE SPEECHESChair: Professor Enrico Tempesta (Osservatorio Permanente sui Giovani e l´Alcool) 08.40 Guest Speaker 08.50 Contextual Drinking. Karen Trocki Ph.D. Alcohol Research Group, Emeryville, CA, USA. 09.20 Discussion. SESSION I – BINGE DRINKINGChair: Professor Philippe De Witte (University of Louvain La Neuve)
09.30 Universal effects of personality-targeted interventions for alcohol misuse: Can you reduce the overall drinking culture in a school by targeting high risk youth in selective prevention? Patricia Conrod, London, UK. (*) 09.50 Brief personalised interventions amongst students. David Foxcroft, Oxford, UK. (*) 10.10 The innate immune system is activated by ‘binge drinking’ in the adolescent rat. Roberta J. Ward, Louvain La Neuve, Belgium. (*) 10.30 Discussion.
11.00 Mid morning break
SESSION II – HEAVY ALCOHOL INTAKE EPISODES
Chair: Dr Kari Poikolainen (Finnish Foundation for Alcohol Studies)
11.30 Concepts, prevalence, and health consequences. Dr Kari Poikolainen, Helsinki, Finland. 11.50 Interplay of genetic and environmental risk factors. Prof Marianne van den Bree, Cardiff, UK. (*) 12.10 Externalizing disorders in adolescence as risk factors. Dr Solja Niemelä, Finland. 12.30 A Bayesian multi-treatment comparison of the efficacy of brief interventions and extended brief interventions for alcohol problems in primary care. Dr Javier Ballesteros, Spain. 12.50 Discussion.
13.00 Lunch Tuesday 19th October 2010SESSION III – PHARMACOLOGICAL TREATMENT OF ALCOHOL DEPENDENCE: FROM BENCH TO BEDSIDE.
Chair: Professor Giovanni Addolorato, M.D. (Catholic University of Rome)
08.30 Examples of animal models of alcoholism and their use in alcohol research. Giancarlo Colombo, Cagliari, Italy. (*) 08.50 Current medications in the treatment of alcohol dependence: a state of art. Otto M. Lesch, Austria. 09.10 New developments of pharmacotherapies in alcohol dependence. Lorenzo Leggio, Rome, Italy. (*) 09.30 Recent developments in identifying neurobiological pathways and treatment targets in alcohol dependence. Rainer Spanagel, Mannheim, Germany. 09.50 Discussion.
10.00 Mid-morning break
SESSION IV ALD: susceptibility and new treatment targets
Chair: Professor Chris Day (University of Newcastle)
10.30 Susceptibility to Alcoholic Liver Disease. Luca Miele, Rome, Italy. (*) 10.50 The TGF beta Signalling Pathway in Alcoholic Liver Disease. Steven Dooley, Heidelberg, Germany. (*) 11.10 Histone acetylation and Alcoholic Liver Disease. Stuart Kendrick, Newcastle, UK. (*) 11.30 The Immune System and Pathogenesis of Alcoholic Liver Disease. Emanuele Albano, Novara, Italy. (*) 11.50 Discussion.
12.00 Lunch
SESSION V – ALCOHOL, CANCER AND EPIDEMIOLOGY
Chair: Associate Professor Matty Weijenberg (University of Maastricht)
14.00 The role of acetaldehyde in the carcinogenic effect of alcohol drinking. Dr Peter Eriksson, Finland. 14.20 The role of lifetime use of alcohol for risk of cancer in the ´European Prospective Investigation into Cancer and Nutrition´ study. Manuela Bergmann, Potsdam-Rehbrücke, Germany. 14.40 Alcohol and lymphatic malignancies. Bas Verhage, Maastricht, The Netherlands. (*)
15.30 Afternoon tea SESSION VI – CARDIOLOGY and ALCOHOL16.00 Beneficial cardiovascular effects of alcohol: How solid is the evidence? Wolfgang Koenig, Ulm, Germany. 16.40 Discussion. 17.00 IMAG CLOSE: (*) Received funding from ERAB
|
|
||||
|
| |||||